Related Experiment Video
Updated: Feb 14, 2026

Ex Vivo Infection of Live Tissue with Oncolytic Viruses
Published on: June 25, 2011
Talimogene laherparepvec: First in class oncolytic virotherapy
Robert M Conry1, Brian Westbrook2, Svetlana McKee1
1a Medicine/Division of Hematology and Oncology, University of Alabama at Birmingham , Birmingham , AL , USA.
Abstract:
Oncolytic viruses represent a novel drug class in which native or modified viruses mediate tumor regression through selective replication within and lysis of tumor cells as well as induction of systemic antitumor immunity capable of eradicating tumor at distant, uninjected sites. Talimogene laherparepvec (TVEC) is a type I herpes simplex virus genetically modified to preferentially replicate in tumor cells, enhance antigen loading of MHC class I molecules and express granulocyte-macrophage colony-stimulating factor to increase tumor-antigen presentation by dendritic cells. It is presently the only oncolytic virus approved by the FDA with an indication for advanced melanoma based upon improved durable response rate in a randomized, phase III trial. Clinical trials are underway in melanoma investigating TVEC as neoadjuvant monotherapy and in combination with checkpoint inhibitors for unresectable disease as well as in an array of other malignancies. It is appropriate to review TVEC's biology mechanism of action, clinical indication and future directions as a prototype of the burgeoning class of oncolytic viruses.
Insights
Oncolytic viruses like talimogene laherparepvec (TVEC) offer a new cancer treatment by destroying tumors and boosting immune responses. TVEC is FDA-approved for advanced melanoma, showing promise for other cancers too.
Area of Science:
- Oncolytic virotherapy
- Cancer immunotherapy
- Viral oncology
Background:
- Oncolytic viruses are a novel drug class for cancer treatment.
- Talimogene laherparepvec (TVEC) is a modified herpes simplex virus.
- TVEC selectively replicates in tumor cells, inducing tumor lysis and systemic antitumor immunity.
Purpose of the Study:
- To review the biology and mechanism of action of TVEC.
- To discuss the clinical indication of TVEC for advanced melanoma.
- To explore future directions for TVEC and other oncolytic viruses.
Main Methods:
- Review of TVEC's genetic modification and biological function.
- Analysis of clinical trial data for TVEC in advanced melanoma.
- Examination of TVEC's role in combination therapies and other malignancies.
Main Results:
- TVEC is the only oncolytic virus approved by the FDA for advanced melanoma.
- Demonstrated improved durable response rate in a randomized, phase III trial.
- Ongoing clinical trials investigate TVEC in neoadjuvant settings and combination therapies.
Conclusions:
- TVEC serves as a prototype for the growing field of oncolytic viruses.
- TVEC's mechanism involves direct tumor cell killing and immune system stimulation.
- Further research is exploring TVEC's potential across various cancers and treatment combinations.
Related Concept Videos
Drug Classes and Categories
Antibody Structure and Classes
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
Antihypertensive Drugs: Thiazide-Class Diuretics
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

